₹293.15
+4.08%NSE close, 16 Nov 2026
−27.75%
Medicamen Biotech is a small cap company, listed on NSE under the symbol MEDICAMEQ. At ₹293.15 a share, the market values the whole company at ₹398 crore.
In FY26, it reported sales of ₹198 crore and a net profit of ₹10 crore, an operating margin of 9.9%. Over the last three years, sales grew 12.0% a year and net profit fell 13.4% a year.
Promoters hold 42.57% of the shares. Foreign institutions hold 4.35%, and domestic institutions, mutual funds among them, 0.00%.
Over the past year the share price has fallen 26.6%, and it is 34.5% below its 52-week high.
₹ crore. Consolidated figures.
The financial results for the period ended September 30, 2026.
Outcome of the Meeting of Preferential Issue Committee of the Board of Directors of Medicamen Biotech Limited ( the Company ) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Outcome/ Summary of proceedings of the 33rd Annual General Meeting of Medicamen Biotech Limited held on 26/09/2026
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| 6M to Sep 2026 |
|---|
| Sales | 46.5 | 47.3 | 43.1 | 44.7 | 45.1 | 29.6 | 43.0 | 47.2 | 46.9 | 60.7 | 47.9 | 103 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 41.6 | 41.6 | 39.6 | 39.4 | 38.4 | 31.2 | 38.4 | 42.0 | 42.5 | 55.2 | 43.6 | 89.7 |
| Operating profit | 4.9 | 5.8 | 3.5 | 5.3 | 6.7 | −1.6 | 4.6 | 5.2 | 4.4 | 5.4 | 4.3 | 13.0 |
| Operating margin | 10.5% | 12.2% | 8.0% | 11.9% | 14.9% | -5.4% | 10.7% | 10.9% | 9.3% | 9.0% | 9.0% | 12.7% |
| Other income | 0.8 | 0.6 | 0.6 | 0.3 | 0.1 | 5.2 | 0.5 | 0.4 | 0.5 | 1.7 | 0.9 | 0.9 |
| Interest | 0.7 | 1.9 | 0.7 | 1.0 | 0.8 | 0.7 | 1.2 | 1.0 | 1.0 | 0.4 | 0.8 | 2.5 |
| Depreciation | 1.8 | 1.8 | 1.8 | 2.6 | 2.2 | 0.5 | 1.8 | 1.9 | 1.8 | 1.7 | 1.8 | 3.7 |
| Profit before tax | 3.3 | 2.7 | 1.6 | 2.0 | 3.9 | 2.5 | 2.1 | 2.7 | 2.1 | 5.1 | 2.6 | 7.7 |
| Tax | 1.2 | 0.6 | 0.8 | 1.1 | 1.0 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.7 | 1.7 |
| Net profit | 2.0 | 2.1 | 1.4 | 1.5 | 2.9 | 2.4 | 2.2 | 2.7 | 2.2 | 3.9 | 2.1 | 5.5 |
| EPS (₹) | 1.60 | 1.61 | 0.63 | 0.71 | 2.30 | 1.47 | 1.18 | 1.56 | 1.21 | 3.28 | 1.36 | 4.40 |
₹ crore, financial years to March.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 115 | 141 | 179 | 163 | 198 |
| Expenses | 91.9 | 117 | 157 | 149 | 178 |
| Operating profit | 23.6 | 23.9 | 22.2 | 13.9 | 19.6 |
| Operating margin | 20.4% | 17.0% | 12.4% | 8.5% | 9.9% |
| Other income | 1.7 | 2.5 | 2.3 | 6.2 | 3.1 |
| Interest | 1.4 | 2.9 | 4.4 | 3.2 | 3.5 |
| Depreciation | 5.8 | 6.4 | 7.1 | 7.1 | 7.2 |
| Profit before tax | 18.1 | 17.1 | 13.1 | 9.9 | 12.0 |
| Tax | 3.2 | 2.3 | 3.6 | 3.3 | 2.2 |
| Net profit | 14.9 | 14.9 | 9.6 | 7.1 | 9.6 |
| EPS (₹) | 12.19 | 11.80 | 7.50 | 5.16 | 7.22 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 4.1 | −7.2 | −33.2 | 13.6 |
| From investing | −8.5 | −1.9 | −3.0 | −0.4 |
| From financing | 4.3 | −1.9 | 63.7 | −9.6 |
| Spent on fixed assets | −8.6 | −2.1 | −4.8 | 0 |
| Free cash flow | −4.5 | −9.3 | −38.0 | 13.6 |
Margins, returns, debt, tax and cash.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net margin | 12.9% | 10.5% | 5.4% | 4.4% | 4.9% |
| Operating margin | 20.4% | 17.0% | 12.4% | 8.5% | 9.9% |
| Return on equity | – | 7.7% | 4.8% | 3.3% | 3.5% |
| Return on capital employed | – | 9.2% | 7.6% | 5.3% | 4.8% |
| Return on assets | – | 5.3% | 3.3% | 2.4% | 2.6% |
| Debt to equity | – | 0.13 | 0.15 | 0.16 | 0.17 |
| Interest coverage | 13.90 | 6.80 | 4.00 | 4.10 | 4.40 |
| Debt to assets | – | 0.09 | 0.10 | 0.11 | 0.13 |
| Current ratio | – | 1.98 | 1.75 | 2.11 | 2.54 |
| Quick ratio | – | 1.43 | 1.10 | 1.31 | 1.75 |
| Cash ratio | – | 0.25 | 0.16 | 0.05 | 0.36 |
| Asset turnover | – | 0.51 | 0.61 | 0.55 | 0.53 |
| Fixed asset turnover | – | 1.54 | 1.97 | 1.89 | 2.35 |
| Inventory turnover | – | – | 1.60 | 1.40 | 1.50 |
| Receivables turnover | – | 2.20 | 3.20 | 2.40 | 2.40 |
| Gross margin | – | – | 48.4% | 47.9% | 48.5% |
| Cash from operations to profit | 28.0% | – | – | -101.0% | -344.0% |
| Effective tax rate | 17.7% | 13.6% | 27.5% | 33.6% | 18.3% |
Submission of Integrated Annual Report for FY 2025-26 and Notice of the 33rd Annual General Meeting ( AGM ) of Medicamen Biotech Limited ( the Company ) to be held through Video Conferencing/Other Audio-Visual Means ( VC/OAVM ) on September 26, 2026
Submission of Business Responsibility and Sustainability Report for the financial year 2025-26
Intimation of Book Closure and Record Date in accordance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )
Closure of Register of Members and Share Transfer Books
Record date for the purpose of Dividend is 19-Sep-2026.
The financial results for the period ended Jun 30, 2026.
A copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.